GW Pharmaceuticals PLC- (GWPH) Given “Buy” Rating at Guggenheim

Guggenheim reissued their buy rating on shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) in a research note released on Tuesday, May 7th, FinViz reports. They currently have a $222.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $186.00.

GWPH has been the topic of several other research reports. BidaskClub upgraded GW Pharmaceuticals PLC- from a hold rating to a buy rating in a research report on Thursday, January 17th. Morgan Stanley reiterated a buy rating on shares of GW Pharmaceuticals PLC- in a research report on Tuesday, April 9th. Piper Jaffray Companies reiterated an overweight rating and set a $185.00 target price on shares of GW Pharmaceuticals PLC- in a research report on Wednesday, February 27th. Zacks Investment Research upgraded GW Pharmaceuticals PLC- from a hold rating to a buy rating and set a $165.00 target price on the stock in a research report on Wednesday, February 6th. Finally, AltaCorp Capital restated an outperform rating on shares of GW Pharmaceuticals PLC- in a report on Monday, January 7th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $205.40.

GWPH stock traded down $3.29 during trading on Tuesday, hitting $173.24. The company had a trading volume of 434,135 shares, compared to its average volume of 473,349. The stock has a market capitalization of $5.25 billion, a PE ratio of -16.41 and a beta of 2.75. GW Pharmaceuticals PLC- has a 1-year low of $90.14 and a 1-year high of $196.00. The company has a quick ratio of 7.19, a current ratio of 7.81 and a debt-to-equity ratio of 0.03.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last issued its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($1.68) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.48) by $0.80. GW Pharmaceuticals PLC- had a negative return on equity of 45.75% and a negative net margin of 458.79%. The firm had revenue of $39.20 million for the quarter, compared to analysts’ expectations of $12.32 million. During the same quarter in the previous year, the firm posted ($3.12) EPS. The firm’s revenue for the quarter was up 1189.5% on a year-over-year basis. Analysts expect that GW Pharmaceuticals PLC- will post -4.76 earnings per share for the current fiscal year.

In related news, insider Volker Knappertz sold 12,144 shares of the company’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $14.64, for a total value of $177,788.16. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Geoffrey W. Dr Guy sold 1,200,000 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $14.69, for a total value of $17,628,000.00. Following the transaction, the insider now directly owns 8,465,528 shares in the company, valued at approximately $124,358,606.32. The disclosure for this sale can be found here. In the last 90 days, insiders sold 2,657,664 shares of company stock worth $39,943,316. Insiders own 5.50% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. US Bancorp DE increased its holdings in shares of GW Pharmaceuticals PLC- by 0.6% during the 1st quarter. US Bancorp DE now owns 11,683 shares of the biopharmaceutical company’s stock worth $1,969,000 after buying an additional 75 shares during the last quarter. Oppenheimer Asset Management Inc. increased its holdings in shares of GW Pharmaceuticals PLC- by 14.9% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 601 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 78 shares during the last quarter. Brandywine Oak Private Wealth LLC increased its holdings in shares of GW Pharmaceuticals PLC- by 6.0% during the 1st quarter. Brandywine Oak Private Wealth LLC now owns 1,435 shares of the biopharmaceutical company’s stock worth $241,000 after buying an additional 81 shares during the last quarter. Belpointe Asset Management LLC increased its holdings in shares of GW Pharmaceuticals PLC- by 6.2% during the 4th quarter. Belpointe Asset Management LLC now owns 1,463 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 85 shares during the last quarter. Finally, Advisory Services Network LLC increased its holdings in shares of GW Pharmaceuticals PLC- by 23.1% during the 4th quarter. Advisory Services Network LLC now owns 511 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 96 shares during the last quarter. Institutional investors and hedge funds own 79.07% of the company’s stock.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Featured Article: Does the discount rate affect the economy?

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.